This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.
Study Type
OBSERVATIONAL
Enrollment
119
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
imaging remission rate of anal fistula
Time frame: Treatment week 0 to 32
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.